A Phase 3 interventional study of Baxdrostat and Placebo in Resistant Hypertension, sponsored by AstraZeneca. Completed at 102 sites in 22 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.
Among the 18 studies testing baxdrostat in Hypertension, this one is the 9th largest by enrollment, is one of 4 that started in 2024, is one of 6 in phase 3, and was the 12th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 197 across the 18 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
71 studies in Hypertension by AstraZeneca: 4 open now, 6 under way, 3 of them phase 3. Of 65 finished, 15 (23%) have results posted.
Among the 71 studies in Hypertension by AstraZeneca, this one is the 20th largest by enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 in phase 3, and was the 63rd registered.
AstraZeneca’s Hypertension studies by the year they started, since 1998.
1 of the studies testing baxdrostat in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing baxdrostat in Hypertension, from their registry updates:
Among AstraZeneca’s 71 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg baxdrostat versus placebo, administered once a day (QD) orally, on the reduction of ambulatory SBP in participants with rHTN, defined as BP targets not being achieved in an individual despite the use of at least 3 antihypertensive agents of different classes (at maximum tolerated dose in the judgement of the Investigator), one of which is a diuretic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 mg baxdrostat administered orally, once daily (QD).
Drug: Baxdrostat
Placebo administered orally, once daily (QD)
Drug: Placebo
Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: • 2 mg per tablet.
Also known as: CIN-107
Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy
Time frame: Baseline to week 12
Change From Baseline in Ambulatory Night-time Average SBP (mmHg) at Week 12 LS Means
Time frame: Baseline to week 12
Change From Baseline in Ambulatory Daytime Average SBP (mmHg) at Week 12
Time frame: Baseline to week 12
Change From Baseline in Seated SBP (mmHg) at Week 12
Time frame: Baseline to week 12
Achieving Ambulatory 24-hour Average SBP of < 130 mmHg at Week 12
Time frame: Baseline to week 12
Change From Baseline in Ambulatory 24-hour Average DBP (mmHg) at Week 12
Time frame: Baseline to week 12
Change From Baseline in Ambulatory Night-time Average DBP (mmHg) at Week 12
Time frame: Baseline to week 12
Change From Baseline in Ambulatory Daytime Average DBP (mmHg) at Week 12
Time frame: Baseline to week 12
Change From Baseline in Seated DBP (mmHg) at Week 12
Time frame: Baseline to week 12
Achieving a Nocturnal SBP Dipping of >= 10% at Week 12
Time frame: Baseline to week 12
Least Square Mean Difference for Change From Baseline in Seated SBP at Week 4
Time frame: Baseline to week 4
Least Square Mean Difference for Change From Baseline in Seated SBP at Week 8
Time frame: Baseline to week 8
Least Square Mean Difference for Change From Baseline in Seated DBP at Week 4
Time frame: Baseline to week 4
Least Square Mean Difference for Change From Baseline in Seated DBP at Week 8
Time frame: Baseline to week 8
| Milestone | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Started | 109 | 109 |
| Started study intervention | 108 | 109 |
| Completed | 103 | 104 |
| Not completed | 6 | 5 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Any other reason | 6 | 3 |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy | -16.6 (-18.8 to -14.3) | -2.6 (-4.7 to -0.4) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Ambulatory Night-time Average SBP (mmHg) at Week 12 LS Means | -16.0 (-18.6 to -13.4) | -2.1 (-4.6 to 0.4) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Ambulatory Daytime Average SBP (mmHg) at Week 12 | -16.8 (-19.2 to -14.4) | -2.7 (-5.1 to -0.4) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Seated SBP (mmHg) at Week 12 | -14.9 (-18.2 to -11.6) | -4.7 (-7.9 to -1.4) |
| Participants | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Achieving Ambulatory 24-hour Average SBP of < 130 mmHg at Week 12 | 60 | 14 |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Ambulatory 24-hour Average DBP (mmHg) at Week 12 | -8.3 (-9.7 to -6.9) | -1.5 (-2.9 to -0.1) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Ambulatory Night-time Average DBP (mmHg) at Week 12 | -7.9 (-9.6 to -6.3) | -1.1 (-2.7 to 0.5) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Ambulatory Daytime Average DBP (mmHg) at Week 12 | -8.4 (-9.9 to -6.9) | -1.7 (-3.2 to -0.3) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Change From Baseline in Seated DBP (mmHg) at Week 12 | -7.6 (-9.5 to -5.7) | -2.6 (-4.5 to -0.7) |
| Participants | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Achieving a Nocturnal SBP Dipping of >= 10% at Week 12 | 36 | 28 |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Least Square Mean Difference for Change From Baseline in Seated SBP at Week 4 | -12.1 (-14.8 to -9.4) | -1.1 (-3.8 to 1.6) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Least Square Mean Difference for Change From Baseline in Seated SBP at Week 8 | -11.6 (-14.5 to -8.6) | -2.4 (-5.4 to 0.6) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Least Square Mean Difference for Change From Baseline in Seated DBP at Week 4 | -5.4 (-7.3 to -3.6) | 0.1 (-1.8 to 1.9) |
| mmHg | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Least Square Mean Difference for Change From Baseline in Seated DBP at Week 8 | -6.1 (-7.8 to -4.3) | -0.5 (-2.3 to 1.2) |
Collected over From the day of randomization until week 14, including 12 weeks double blind treatment period and 2 weeks safety follow-up.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baxdrostat 2 mg | 0/108 (0%) | 1/108 (0.9%) | 56/108 (51.9%) |
| Placebo | 0/109 (0%) | 1/109 (0.9%) | 39/109 (35.8%) |
| Event | Baxdrostat 2 mg | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/108 | 0/109 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/108 | 1/109 |
| Event | Baxdrostat 2 mg | Placebo |
|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 11/108 | 3/109 |
| HeadacheNervous system disorders | 6/108 | 3/109 |
| HypotensionVascular disorders | 5/108 | 0/109 |
| HypokalaemiaMetabolism and nutrition disorders | 0/108 | 5/109 |
| HypertensionVascular disorders | 0/108 | 4/109 |
| DiarrhoeaGastrointestinal disorders | 3/108 | 1/109 |
| FatigueGeneral disorders | 3/108 | 1/109 |
| Influenza like illnessGeneral disorders | 3/108 | 1/109 |
| InfluenzaInfections and infestations | 3/108 | 0/109 |
| Urinary tract infectionInfections and infestations | 3/108 | 0/109 |
| Age, Continuous(Age (years)) | Baxdrostat 2 mg | Placebo | Total |
|---|---|---|---|
| Age (years) | 59.4 ± 11.2 | 59.7 ± 12.4 | 59.6 ± 11.8 |
| Sex: Female, Male(Participants) | Baxdrostat 2 mg | Placebo | Total |
|---|---|---|---|
| Female | 38 | 39 | 77 |
| Male | 70 | 70 | 140 |
| Race (NIH/OMB)(Participants) | Baxdrostat 2 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 16 | 19 | 35 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 6 | 10 |
| White | 86 | 84 | 170 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Baxdrostat 2 mg | Placebo | Total |
|---|---|---|---|
| ARG | 12 | 13 | 25 |
| AUS | 2 | 6 | 8 |
| BEL | 0 | 1 | 1 |
| BGR | 8 | 11 | 19 |
| CAN | 0 | 4 | 4 |
| CZE | 6 | 4 | 10 |
| DEU | 2 | 1 | 3 |
| ESP | 5 | 3 | 8 |
| GBR | 9 | 9 | 18 |
| GRC | 7 | 10 | 17 |
| HUN | 3 | 0 | 3 |
| MYS | 3 | 0 | 3 |
| PHL | 1 | 2 | 3 |
| POL | 8 | 5 | 13 |
| SAU | 3 | 3 | 6 |
| SVK | 2 | 1 | 3 |
| THA | 4 | 4 | 8 |
| TUR | 10 | 9 | 19 |
| TWN | 4 | 2 | 6 |
| USA | 15 | 12 | 27 |
| VNM | 2 | 7 | 9 |
| ZAF | 2 | 2 | 4 |
Showing the first 100 of 102 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Mar 2024 to primary completion in Aug 2025, 17 months.
Results were first posted in Aug 2026, 11 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 17 months is close to that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baxdrostat